Fig. 1
From: A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model
Experimental design investigating an engineered medium-chain fatty acid analogue, SEFA-6179, in a murine model of PN-associated liver disease and endotoxin challenge. Mice were randomized to parenteral nutrition-equivalent intake or standard rodent chow. Mice received various intravenous (saline or soybean oil-based lipid emulsion i.e. Intralipid), oral gavage (MCT or SEFA-6179), and intraperitoneal (saline or LPS) treatments. A total of n = 70 C57Bl/6J mice were utilized (n = 5 per group, total of 14 groups). MCT, medium-chain triglyceride; SEFA-6179, structurally engineered fatty acid-6179; LPS, lipopolysaccharide (E. coli).
